Which company produces Lynparza/Olaparib?

Olaparib/Olaparib (Olaparib) is a targeted anti-cancer drug developed by Professor Stephen Jackson and his team at the University of Cambridge in the UK, and introduced for clinical use for the first time by the biotechnology company KuDOS Pharmaceuticals founded by him. In 2006, AstraZeneca acquired KuDOS, which enabled the rapid development and promotion of the drug. Later, AstraZeneca and Merck & Co. jointly conducted further clinical development of olaparib.

Olaparib's main mechanism of action is to inhibit polyadenosine5'-bisphosphate ribose polymerase (PARP), a key enzyme involved in DNA repair. By inhibiting PARP, olaparib can interfere with the DNA repair ability of tumor cells, causing cancer cells carrying BRCA gene mutations to be more susceptible to damage, thus promoting cell apoptosis. Studies show that olaparib is particularly effective in patients with advanced ovarian cancer, especially those who have undergone multiple rounds of chemotherapy.

In December 2014, olaparib was approved by the U.S. Food and Drug Administration (FDA), becoming the first monotherapy approved for advanced ovarian cancer with germline BRCA mutations (gBRCAm). The approval was based on its efficacy in clinical trials, particularly in patients who have received three or more chemotherapy treatments.

Olaparib is commonly administered as tablets, taken twice daily with or without food. Due to its special mechanism of action, olaparib has not only been successful in the treatment of ovarian cancer, but researchers are also exploring its application potential in other types of cancer. For example, early research shows that olaparib may also be effective in patients with breast, pancreatic, prostate and other types of cancer, especially those with BRCA mutations.